Compare ALTO & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTO | VCRE |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.7M | 271.7M |
| IPO Year | 2005 | 2026 |
| Metric | ALTO | VCRE |
|---|---|---|
| Price | $2.98 | $9.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.33 | ★ $24.45 |
| AVG Volume (30 Days) | ★ 1.0M | 16.7K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.51 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $917,927,000.00 | N/A |
| Revenue This Year | $5.33 | $38.94 |
| Revenue Next Year | $1.09 | $694.23 |
| P/E Ratio | $8.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.08 | $7.88 |
| 52 Week High | $6.11 | $14.01 |
| Indicator | ALTO | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 25.61 | 42.49 |
| Support Level | N/A | $8.83 |
| Resistance Level | $3.85 | $9.64 |
| Average True Range (ATR) | 0.21 | 0.44 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 7.54 | 12.45 |
Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.